Quest Diagnostics Incorporated (DGX) Financials
DGX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 14.0 billion | 7.5 billion |
2023-12-31 | 14.0 billion | 7.6 billion |
2023-09-30 | 13.5 billion | 6.9 billion |
2023-06-30 | 13.4 billion | 7.1 billion |
DGX Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 50.0 million | 22.0 million |
2023-12-31 | 455.0 million | 19.0 million |
2023-09-30 | 102.0 million | 18.0 million |
2023-06-30 | 340.0 million | 16.0 million |
DGX Net Income
Date | Net Income |
---|---|
2024-03-31 | 208.0 million |
2023-12-31 | 192.0 million |
2023-09-30 | 237.0 million |
2023-06-30 | 249.0 million |
DGX Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 474.0 million | - | 642.0 million |
2023-12-31 | 686.0 million | - | 656.0 million |
2023-09-30 | 143.0 million | 3.9 billion | 662.0 million |
2023-06-30 | 126.0 million | 3.8 billion | 664.0 million |
DGX Shares Outstanding
DGX Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 104.0 million | - | 440.0 million | - |
2023-12-31 | 72.0 million | - | 407.0 million | - |
2023-09-30 | 105.0 million | - | 376.0 million | - |
2023-06-30 | 104.0 million | - | 416.0 million | - |
DGX Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 2.4 billion | 1.6 billion |
2023-12-31 | 2.3 billion | 1.5 billion |
2023-09-30 | 2.3 billion | 1.5 billion |
2023-06-30 | 2.3 billion | 1.5 billion |
DGX
List: Contenders
Price: $137.38
Dividend Yield: 0.02%
Forward Dividend Yield: 2.18%
Payout Ratio: 40.05%
Dividend Per Share: 3.00 USD
Earnings Per Share: 7.43 USD
P/E Ratio: 17.05
Exchange: NYQ
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 1.3 million
Ebitda: 346.0 millionMarket Capitalization: 15.3 billion
Average Dividend Frequency: 4
Years Paying Dividends: 21
DGR3: 7.59%
DGR5: 6.76%
DGR10: 8.22%